High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: A multicenter experience from China

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 251-259

  Huang, Bin Tao ^a   Zeng, Qing Chun ^b   Yu, Jessica ^c   Liu, Xiao Li ^a   Xiao, Zhen ^d   Zhu, Hong Qian ^e  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

^d INNER MONGOLIA MEDICAL COLLEGE   (China)

^e GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; Daunorubicin; Effect; Homoharringtonine; Security; Toxicity

Indexed keywords

ARABINOSIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGRANULOCYTOSIS; AIRWAY EDEMA; ALOPECIA; ARTICLE; BRONCHOSPASM; CANCER CLASSIFICATION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINA; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; GERIATRIC PATIENT; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUTH LESION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; SKIN ABRASION; SKIN DISEASE; SKIN REDNESS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT DISEASE;

AGED; ANTINEOPLASTIC AGENTS; CHINA; DAUNORUBICIN; FEMALE; HARRINGTONINES; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84864061069     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9820-4     Document Type: Article

References (32)

1. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521-8. (Pubitemid 36986953)
2. Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;29:609-15. (Pubitemid 40603559)
3. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129-35. (Pubitemid 46900774)
4. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361:1235-48.
5. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548-53.
6. Qian SX, Li JY, Wu HX. Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:209-13.
7. Löwenberg B, Downing Jr. Burnett A: acute myeloid leukemia. N Engl J Med. 1999;341:1051-62.
8. Zhang ZY. Clinical analysis of the therapeutic effect of semi-synthetic harringtonine in treating 55 cases of nonlymphocytic leukemia. Chin M Ed J. 1987;100:565-8.
9. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, et al. Homoharringtonine in combination with cytarabine and aclaru-bicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006;20:1361-7. (Pubitemid 44084048)
10. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5:723-31.
11. Luo CY, Tang JY, Wang YP. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology. 2004;9:259-70. (Pubitemid 39359346)
12. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly (ADPri-bose) polymerase (PARP). Am J Hematol. 2004;76:199-204. (Pubitemid 38828836)
13. Ma Y, Wang X, Xu X. World Health Organization sub-types, initial treatment outcome and prognostic study of unselected adult patients with acute myeloid leukaemia in Shanghai: an analysis of 623 cases. J Int Med Res. 2009;37:1191-201.
14. Wu L, Li X, Su J, Chang C, He Q, Zhang X, et al. Effect of standard-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma. 2009;50:1461-7.
15. Bian SG, Hao YS, Wang ZC. Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia. Zhonghua Nei Ke Za Zhi. 1990;29:22-5.
16. Coonley CJ, Warrell RP Jr, Young CW. Phase I trial of homo-harringtonine administered as a 5-day continuous infusion. Cancer Treat Rep. 1983;67:693-6. (Pubitemid 13001716)
17. Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, et al. NCCN practice guidelines for acute myelogenous leukemia. Oncology. 2000;14:53-61.
18. Vardiman JW, Harris NL, Brunning RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-303.
19. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984;68:1085-91. (Pubitemid 14027401)
20. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329-37. (Pubitemid 46477296)
21. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9. (Pubitemid 46594039)
22. Xu W, Tang Y, Song H, Shi S, Yang S. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688-93. (Pubitemid 47549180)
23. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397-403.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
25. Wang J, Lü S, Yang J, Song X. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol. 2009;30:32-4.
26. Meadows AT, Kramer S, Hopson R, Lustbader E, Jarrett P, Evans AE. Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest. 1983;1:49-55. (Pubitemid 13083531)
27. Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child. 1989;64:657-61. (Pubitemid 19127661)
28. Katz LM, Howell JB, Doyle JJ, Stern LS, Rosenblatt LC, Piech CT, et al. Outcomes and charges of elderly patients with acute myeloid leukemia. Am J Hematol. 2006;81:850-7. (Pubitemid 44682187)
29. Haus O, Kotlarek-Haus S, Duszeńko E, Makowska I, Potoczek S, Nowak E, et al. Cytogenetic changes and their prognostic significance in elderly acute myeloid leukemia. Pol Arch Med Wewn. 2003;109:571-7. (Pubitemid 36874887)
30. Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E. Potential chemotherapy side effects: what do oncologists tell parents? Pediatr Blood Cancer. 2009;52:497-502.
31. Neidhart JA, Young DC, Derocher D, et al. Phase I trial of ho-moharringtonine. Cancer Treat Rep. 1983;67:801-4.
32. O'Brien S, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86:3322-6.